Francesca Iacovella
Overview
Explore the profile of Francesca Iacovella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maritati F, Corradetti V, Bini C, Provenzano M, Cuna V, Busutti M, et al.
Kidney Int Rep
. 2024 May;
9(4):982-993.
PMID: 38765562
Introduction: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft...
2.
Cianciolo G, Tondolo F, Barbuto S, Angelini A, Ferrara F, Iacovella F, et al.
Clin Kidney J
. 2022 Jul;
15(8):1459-1474.
PMID: 35892022
Chronic kidney disease mineral and bone disorder may persist after successful kidney transplantation. Persistent hyperparathyroidism has been identified in up to 80% of patients throughout the first year after kidney...
3.
Cianciolo G, Tondolo F, Barbuto S, Angelini A, Ferrara F, Iacovella F, et al.
Clin Kidney J
. 2022 Jun;
15(7):1437.
PMID: 35759738
[This corrects the article DOI: 10.1093/ckj/sfac050.].
4.
Capelli I, Iacovella F, Ghedini L, Aiello V, Napoletano A, Marconi L, et al.
In Vivo
. 2022 Jun;
36(4):1994-1997.
PMID: 35738624
Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) may require specific therapy with vasopressin receptor antagonists to slow the progression of renal disease. Because of its mechanism of action,...
5.
Cianciolo G, Barbuto S, Iacovella F, La Manna G, Galassi A, Ciceri P, et al.
Drugs Today (Barc)
. 2022 Feb;
58(1):33-53.
PMID: 35107092
Hyperphosphatemia is a common feature in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease (ESRD). Commonly, high serum phosphate levels are observed only in later...
6.
Cianciolo G, Tondolo F, Barbuto S, Iacovella F, Zavatta G, Altieri P, et al.
Am J Nephrol
. 2021 Sep;
52(8):611-619.
PMID: 34518468
Introduction: Denosumab represents a realistic treatment option to increase bone mineral density in kidney transplant recipients (KTRs). It is still unknown how and at what extent posttransplantation bone disease and...
7.
Angelini A, Cappuccilli M, Magnoni G, Chiocchini A, Aiello V, Napoletano A, et al.
G Ital Nefrol
. 2021 Sep;
38(4).
PMID: 34469084
Patients with chronic kidney disease or end-stage renal disease experience tremendous cardiovascular risk. Cardiovascular events are the leading causes of death in these patient populations, thus the interest in non-traditional...
8.
Cianciolo G, Cappuccilli M, Tondolo F, Gasperoni L, Zappulo F, Barbuto S, et al.
Nutrients
. 2021 Apr;
13(5).
PMID: 33922902
Poor vitamin D status is common in patients with impaired renal function and represents one main component of the complex scenario of chronic kidney disease-mineral and bone disorder (CKD-MBD). Therapeutic...